ClinicalTrials.gg
CompletedNCT06812754Updated Mar 19, 2026

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

A Phase 2 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Astellas Pharma Global Development, Inc.. Completed at 26 sites in China. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
11th of 16
150 · median 249
Started
2025
with 1 other
Phase 2
5 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
6 of 16
Astellas Pharma Global Development, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 11th largest by enrollment, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 12th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed.

The goal of this study is to confirm if fezolinetant helps reduce hot flashes in Chinese women going through menopause. This study will also confirm the safety of fezolinetant and how well the women cope with (tolerate) the treatment. The women will take 1 tablet of the study medicine either fezolinetant or placebo once a day for up to 12 weeks. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.

Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. During the study, the women will visit the study clinic several times. At each visit they will be asked if they had any medical problems. The women will have general safety checks. At some visits, a breast ultrasound (mammogram), cervical smear, and ultrasound of the womb (uterus) may be done.

The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or placebo).

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • ESN364
  • vasomotor symptoms
  • fezolinetant
  • VEOZAH™
  • menopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a >/= 16 kg/m2 and \</= 38 kg/m2 at screening visit.
  • Participant must be seeking treatment or relief for vasomotor symptom(s) (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

    • Spontaneous amenorrhea for >/= 12 consecutive months
    • Spontaneous amenorrhea for >/= 6 months with biochemical criteria of menopause (follicle-stimulating hormone (FSH) > 40 IU/L); or
    • Having had bilateral oophorectomy >/= 6 weeks prior to the screening visit (with or without hysterectomy).
    • FSH > 40 IU/L if participants received hysterectomy but still have an ovary/ovaries.
  • Within the 10 days prior to randomization, participant must have a minimum average of 7 moderate to severe hot flash(es) (HFs) (VMS) per day (data must be available for at least 7 of the last 10 days prior to randomization).
  • Participant is in good general health as determined on the basis of medical history and general physical examination, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and (ECG) within the reference range for the population studied, or showing no deviations.
  • Participant has documentation of a normal/negative or no clinically significant findings mammogram (or breast ultrasound) (e.g., \< Breast Imaging-Reporting and Data System (BI-RADS) class 4; obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.
  • Participant is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and week 12 (end of treatment (EOT)), and for participants who are withdrawn from the study prior to completion, a TVU at the early discontinuation (ED) visit. This is not required for participants who have had a partial (supracervical) or total hysterectomy.
  • Participant has documentation of a normal or not clinically significant Pap test (or equivalent cervical cytology) within the previous 12 months of study enrollment or at screening. This is not required for participants who have had a total hysterectomy.
  • Participant has a negative urine pregnancy test at screening; this is not required for participants who have had a total hysterectomy.
  • Participant has a negative serology panel [i.e., negative surface antigen (HBsAg) and negative virus antibody (HCVAb) screens] at screening.
  • Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Participant has known substance abuse or alcohol addiction within 6 months of screening.
  • Participant has a current , with exception of non- basal cell carcinoma of the skin.
  • Participant has a history of malignancy with exceptions of at least 5 years post-treatment and without known recurrence.
  • For participants with a uterus: Participant has an unacceptable result from the TVU assessment at screening, i.e., full length of endometrial cavity cannot be visualized or presence of a finding.
  • Participant has a history within the last 6 months of undiagnosed uterine bleeding.
  • Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.
  • Participant has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening [visit 1].
  • Participant has previously been enrolled in a clinical trial with fezolinetant or other neurokinin (NK) receptor antagonists.
  • Participant uses a prohibited therapy (strong and moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy (HRT), hormonal or any treatment for VMS [prescription, over-the-counter, or herbal]) or is not willing to wash-out and discontinue use of such drugs for the full duration of study conduct.
  • Participant has received any therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Participant has uncontrolled hypertension, defined as systolic blood pressure >/=140 mmHg or diastolic blood pressure as >/= 90 mmHg based on an average of 2 to 3 readings within the screening period.

    • Participants with a medical history of hypertension who are well controlled may be enrolled
    • Participants who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures
  • Participant has active liver disease, jaundice, elevated liver aminotransferases ( (ALT) or aspartate aminotransferase (AST)), elevated total or direct , elevated (INR) or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 × (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin (TBL) may be enrolled as long as hemolysis is ruled-out (i.e., direct bilirubin, and reticulocytes are normal).
  • Participant has creatinine > 1.5 × ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula \</=30 mL/min/1.73 m2 at screening.
  • Participant has a positive result for (HIV) at screening.
  • Participant has any condition which makes the participant unsuitable for study participation.
  • Participant is unable or unwilling to complete the study procedures.
  • Participant has a known or suspected to fezolinetant or any components of the formulation used.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Fezolinetant

    Participants will receive fezolinetant once daily for 12 weeks.

    Drug: Fezolinetant

  • Placebo comparator
    Placebo

    Participants will receive matching placebo once daily for 12 weeks.

    Drug: Placebo

Interventions

  • oral

    Also known as: ESN364, VEOZAH™

  • DrugPlacebo

    oral

06

What researchers measure

Primary outcomes

  1. Mean change in the frequency of moderate to severe Vasomotor Symptoms (VMS) from baseline to week 12

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Mean change in the frequency of moderate to severe VMS from baseline to each week up to week 12

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  2. Mean change in the severity of moderate to severe VMS from baseline to week 12

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 12

  3. Mean change in the severity of moderate to severe VMS from baseline to each week up to week 12

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  4. Mean percent reduction in the frequency of moderate to severe VMS from baseline to each week up to week 12

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Mean percent reduction will be reported.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  5. Percent reduction >/= 50% in the frequency of moderate to severe VMS from baseline to each week up to week 12

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day. Percent reduction of \>/= 50% will be reported.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  6. Percent reduction at 100% in the frequency of moderate to severe VMS from baseline to each week up to week 12

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate and severe VMS events per day. Percent reduction of 100% will be reported.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  7. Number of participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

    Time frame: Up to Week 15

  8. Change from baseline in endometrial thickness in post-menopausal participants

    Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).

    Time frame: Baseline up to Week 12

  9. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to Week 15

  10. Number of participants with vital sign abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to Week 15

  11. Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to Week 12

  12. Pharmacokinetics (PK) of Fezolinetant in plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Up to Week 12

  13. Pharmacokinetics (PK) of metabolite ES259564 in plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Up to Week 12

  14. Change in serum concentrations of sex hormones

    Sex hormone biomarker levels will be recorded from serum samples.

    Time frame: Baseline up to Week 15

07

Study locations

26 sites
  • Beijing Hospital
    Beijing, Beijing Municipality, China
  • Capital Medical University (CMU) - Beijing Shijitan Hospital
    Beijing, Beijing Municipality, China
  • Capital Medical University - Beijing Obstetrics and Gynecology Hospital
    Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
  • Guangzhou Medical University - The Third Affiliated Hospital
    Guangzhou, Guangdong, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong, China
  • Shenzhen Maternal & Child Health Hospital
    Shenzhen, Guangdong, China
  • Guangxi Medical University (GXMU) - Liuzhou Renmin Hospital
    Liuzhou, Guangxi, China
  • Liuzhou Worker's Hospital
    Liuzhou, Guangxi, China
  • Hainan Women and Children's Medical Center
    Haikou, Hainan, China
  • The second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Hunan Provincial Maternal and Child Health Care Hospital
    Changsha, Hunan, China
  • Xiangya Hospital, Central South University
    Zhuzhou, Hunan, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • Southeast University, ZhongDa Hospital
    Nanjing, Jiangsu, China
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi, China
  • Jilin Province FAW General Hospital
    Changchun, Jilin, China
  • Jinan Central Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong, China
  • Shandong Provincial Hospital
    Jinan, Shandong, China
  • Shanghai First Maternity and Infant Hospital
    Shanghai, Shanghai Municipality, China
  • Shanxi Woman and Children Hospital
    Taiyuan, Shanxi, China
  • The First hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality, China
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Feb 2026, 11 months.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 6, 2025
StartActual
Mar 10, 2025
Primary completionActual
Feb 11, 2026
CompletionActual
Mar 5, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06812754
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Mar 10, 2025
Primary completion
Feb 11, 2026
Completion
Mar 5, 2026
Last update
Mar 19, 2026

Study contacts

Study Physician
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion